2018
Targeting the ErbB Family in Head and Neck Cancer
Kiseleva A, Beck T, Serebriiskii I, Liu H, Burtness B, Golemis E. Targeting the ErbB Family in Head and Neck Cancer. Current Cancer Research 2018, 7-61. DOI: 10.1007/978-3-319-78762-6_2.Peer-Reviewed Original ResearchPI3K/Akt/mTORSquamous cell carcinomaErbB receptor tyrosine kinase familyNovel therapeutic approachesAkt/mTORErbB family receptorsJAK1/STAT3PLC/PKCErbB family membersEGFR therapyCell carcinomaCommon therapyNeck cancerReceptor tyrosine kinase familyTherapeutic approachesNew therapiesCancer growthAbnormal expressionFamily receptorsTherapyTyrosine kinase familySCCHNErbB familyNormal cellsFamily members
2014
Overview: The Pathobiology of Head and Neck Cancer
Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2014, 1-5. DOI: 10.1007/978-1-4614-8815-6_1.Peer-Reviewed Original ResearchSquamous cell cancerSquamous cell carcinomaHigh recurrence ratePathobiology of headPotential therapeutic targetEarly-stage cancerMultimodality therapyCell cancerRecurrence rateCell carcinomaNeck cancerDevastating cancerMetastatic cancerStage cancerDifficult diseaseTherapeutic targetSubglottic larynxCancerProtein expression changesDiseaseNeckExpression changesImproved managementHeadSCCHN
2007
EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN)
Kies M, Ghebremichael M, Katz T, Herbst R, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Journal Of Clinical Oncology 2007, 25: 6024-6024. DOI: 10.1200/jco.2007.25.18_suppl.6024.Peer-Reviewed Original ResearchHigh EGFR expressionEGFR expressionRecurrent SCCHNTumor samplesCisplatin-based chemotherapySquamous cell carcinomaAssociation of responsePercentage of cellsHazard ratioProgressive diseaseCisplatin therapyPatient selectionCell carcinomaHigher eGFREGFR immunoreactivityInitial cohortCetuximabChemotherapyIndependent cohortFurther enrollmentPatientsSurvival analysisTumor resistanceDako kitSCCHN